PMID- 32442020
OWN - NLM
STAT- MEDLINE
DCOM- 20211118
LR  - 20211118
IS  - 1615-7109 (Electronic)
IS  - 1203-4754 (Linking)
VI  - 24
IP  - 5
DP  - 2020 Sep/Oct
TI  - Short-Term Evaluation of the Real-World Efficacy and Safety of Dupilumab for the 
      Treatment of Moderate-to-Severe Atopic Dermatitis: A Canadian Multicenter 
      Retrospective Cohort Study [Formula: see text].
PG  - 468-473
LID - 10.1177/1203475420928907 [doi]
AB  - BACKGROUND: Systemic therapy for atopic dermatitis (AD) has been challenging with 
      limited safe and efficacious long-term treatment options. In 2017, dupilumab was 
      approved in the United States, Europe, and Canada as the first targeted therapy 
      for patients with moderate-to-severe AD. Despite promising efficacy and safety 
      results in clinical trials, our understanding of dupilumab in clinical practice 
      remains limited with few studies outside clinical trials in literature. 
      OBJECTIVE: The aim of this study is to evaluate the efficacy and safety of 
      dupilumab in clinical practice and discuss any differences in results between 
      clinical trials and real-world results. METHODS: A retrospective chart review was 
      conducted of consecutive patients receiving dupilumab treatment at two tertiary 
      hospitals in Toronto, Canada, between December 2017 and May 2019. The primary 
      efficacy endpoint was measured by Investigator's Global Assessment (IGA) score of 
      0/1 at 16 weeks and all adverse events (AEs) experienced by patients were 
      recorded. RESULTS: Of the 93 patients included in the study, 51 (55%) reached IGA 
      0/1 and 38 (41%) experienced >/=1 AE. There were no severe AEs or discontinuation 
      prior to 16 weeks due to an AE. CONCLUSIONS: These findings suggest a higher 
      IGA-based efficacy profile with no newly identified safety concerns in patients 
      treated with dupilumab at two tertiary hospitals in Toronto, Canada, compared to 
      those in randomized controlled trials.
FAU - Jo, Christine E
AU  - Jo CE
AUID- ORCID: 0000-0001-7866-1050
AD  - 6363 University of Ottawa, ON, Canada.
FAU - Georgakopoulos, Jorge R
AU  - Georgakopoulos JR
AUID- ORCID: 0000-0002-6844-2724
AD  - 793812365 Division of Dermatology, Department of Medicine, University of Toronto, 
      ON, Canada.
FAU - Ladda, Matthew
AU  - Ladda M
AUID- ORCID: 0000-0002-5128-2488
AD  - University of Toronto, ON, Canada.
FAU - Ighani, Arvin
AU  - Ighani A
AUID- ORCID: 0000-0002-2164-3609
AD  - 793812365 Division of Dermatology, Department of Medicine, University of Toronto, 
      ON, Canada.
FAU - Mufti, Asfandyar
AU  - Mufti A
AD  - 793812365 Division of Dermatology, Department of Medicine, University of Toronto, 
      ON, Canada.
FAU - Drucker, Aaron M
AU  - Drucker AM
AD  - 793812365 Division of Dermatology, Department of Medicine, University of Toronto, 
      ON, Canada.
AD  - 798512366 Women's College Hospital, Toronto, ON, Canada.
FAU - Piguet, Vincent
AU  - Piguet V
AD  - 793812365 Division of Dermatology, Department of Medicine, University of Toronto, 
      ON, Canada.
AD  - 798512366 Women's College Hospital, Toronto, ON, Canada.
FAU - Yeung, Jensen
AU  - Yeung J
AD  - 793812365 Division of Dermatology, Department of Medicine, University of Toronto, 
      ON, Canada.
AD  - 798512366 Women's College Hospital, Toronto, ON, Canada.
AD  - 7938 Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
AD  - Probity Medical Research Inc., Waterloo, ON, Canada.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200522
PL  - United States
TA  - J Cutan Med Surg
JT  - Journal of cutaneous medicine and surgery
JID - 9614685
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 420K487FSG (dupilumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Dermatitis, Atopic/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Ontario
MH  - Retrospective Studies
MH  - Severity of Illness Index
OTO - NOTNLM
OT  - adult
OT  - atopic dermatitis
OT  - biologic
OT  - dupilumab
OT  - real world
EDAT- 2020/05/23 06:00
MHDA- 2021/11/19 06:00
CRDT- 2020/05/23 06:00
PHST- 2020/05/23 06:00 [pubmed]
PHST- 2021/11/19 06:00 [medline]
PHST- 2020/05/23 06:00 [entrez]
AID - 10.1177/1203475420928907 [doi]
PST - ppublish
SO  - J Cutan Med Surg. 2020 Sep/Oct;24(5):468-473. doi: 10.1177/1203475420928907. Epub 
      2020 May 22.